Medicare AdvantagePrior AuthMedium impact
Kuvan® (sapropterin) (Revised)
Humana·Genetics, Pediatrics, Pharmacy·Medicare Advantage
Effective date
Jan 1, 2022
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its Kuvan (sapropterin) prior authorization policy effective January 1, 2022, with updates as of August 27, 2025. The policy requires prior authorization for all Kuvan brand formulations, generic sapropterin, Javygtor, and Zelvysia products. Brand-name requests now require documented evidence of prior treatment failure, contraindication, or intolerance to generic sapropterin. This is a maintenance revision clarifying existing coverage criteria for PKU treatment.
Action Required
Immediately: Billing and clinical teams must ensure all Kuvan (sapropterin) pharmacy requests for Medicare Advantage members include prior authorization submission. For brand formulation requests (Kuvan, Javygtor, Zelvysia), documentation must prove the member has had prior treatment with generic sapropterin OR has a documented contraindication or intolerance to generic formulation. Update pharmacy billing system to flag brand requests requiring additional documentation. Route all brand-name sapropterin requests through prior auth process with supporting documentation attached. Failure to obtain prior authorization will result in claim denials. Communicate this requirement to prescribing providers, especially those treating PKU patients.